Skip to main content
Premium Trial:

Request an Annual Quote

Kindstar, ACD Partner on RNA-based MDx

NEW YORK (GenomeWeb News) – Kindstar Global will validate and implement Advanced Cell Diagnostics' RNAscope technology-based molecular diagnostic assays as part of a partnership the firms announced today.

The firms said that the deal will allow Kindstar to leverage ACD's RNA biomarker analysis platform to offer new cancer diagnostic tests to the 3,300-plus hospitals in Kindstar's network in China.

Initially, the tests being launched include RNAscope HPV, a high-risk HPV test for assessing HPV status in cervical pre-cancer and head and neck cancer, as well as CTCscope for the detection and characterization of circulating tumor cells in blood.

"The new RNAscope-based tests will significantly broaden Kindstar’s oncology test menu offerings," Kindstar Founder and CEO Shiang Huang said in a statement. "The RNAscope platform will also allow Kindstar to more rapidly translate today's advances in cancer research into clinical practice for our physicians and patients."

Financial and other terms of the agreement were not disclosed.

Kindstar provides esoteric diagnostic testing services in China. ACD, based in Hayward, Calif., develops cell and tissue-based research tools.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.